why choose us

First received: June 09, 2023

Clinical Trial: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Recurrent Mantle Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): A Phase II Study With Safety Lead-In

Brief Summary: This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory).Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.Lenalidomide is in a class of medications called immunomodulatory agents.It works by helping the immune system kill cancer cells.Venetoclax is in a class of…

Read more